TRex Bio raises $116.7 million in IPO priced at $14 a share
As seen on the 24/7 Wall St. homepage on October 9, 2026.
TRex Bio prices IPO at $14, raising $116.7 million
TRex Bio priced at $14 a share, pulling in roughly $116.7 million with J.P. Morgan and Evercore leading the book. The immunology developer's deal lands with shares already allocated, so the first chance for public investors comes when it starts trading.
Continue ReadingShow less
TRex Bio, Inc. priced its initial public offering at $14 per share, and J.P. Morgan and Evercore led the offering as joint book-running managers, a pairing that signals institutional confidence in the deal's distribution.
The company operates in immunology, a field that has drawn sustained investor interest given the complexity and commercial potential of immune-system-targeting therapies. With shares fully allocated at pricing, the supply-demand dynamic heading into the first day of trading is worth watching closely.
For public investors, the open market is the first opportunity to buy, since all shares were distributed to institutional and other pre-IPO buyers through the book-building process.
The SEC filing tied to this offering is publicly available and contains the full prospectus, including details on TRex Bio's pipeline, use of proceeds, and risk factors that any prospective investor should review before the stock begins trading.